Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7221864 | 1.00 | RNASE1 (0.48) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL15061820 | 0.89 | RNASE1 (0.44) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL14397161 | 0.89 | RNASE1 (0.38) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL2619370 | 0.89 | RNASE1 (0.43) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL20810838 | 0.89 | RNASE1 (0.43) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL20810870 | 0.89 | RNASE1 (0.43) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL2611630 | 0.88 | RNASE1 (0.42) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL2122164 | 0.88 | RNASE1 (0.42) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL2122161 | 0.88 | RNASE1 (0.42) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL4729467 | 0.87 | RNASE1 (0.42) | RNASE1LMNASMN1; SMN2ALOX12ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669538-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION A/S (DK) | 2020-06-02 | — | — | US | disclosed |
| US-20170198283-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION A/S (DK) | 2017-07-13 | — | — | US | disclosed |
| US-9688980-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION (DK) | 2017-06-27 | — | — | US | disclosed |
| EP-2305808-B1 | Templated molecules and methods for using such molecules | NUEVOLUTION AS (DK) | 2016-03-02 | — | — | EP | disclosed |
| EP-1905829-B1 | Templated molecules and methods for using such molecules | NUEVOLUTION AS (DK) | 2016-02-17 | — | — | EP | disclosed |
| US-20150315567-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION A/S (DK) | 2015-11-05 | — | — | US | disclosed |
| US-8932992-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION A/S (DK) | 2015-01-13 | — | — | US | disclosed |
| EP-2305808-A1 | Templated molecules and methods for using such molecules | Nuevolution A/S (DK) | 2011-04-06 | — | — | EP | disclosed |
| US-7727713-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION A/S (DK) | 2010-06-01 | — | — | US | disclosed |
| US-20100016177-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| EP-1905829-A2 | Templated molecules and methods for using such molecules | Nuevolution A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| EP-1402024-B1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION AS (DK) | 2007-08-22 | — | — | EP | disclosed |
| US-20040049008-A1 | Templated molecules and methods for using such molecules | NUEVOLUTION A/S (DK) | 2004-03-11 | — | — | US | disclosed |
| US-6627456-B1 | Incorporating into the oligonucleotide analogs that are the components of a library to which in vitro selection methods functionalized standard and non-standard nucleotides, and incorporating functionalized cofactors into the experiment | BENNER, STEVEN | 2003-09-30 | — | — | US | disclosed |
| US-5965364-A | Method for selecting functional deoxyribonucleotide derivatives | BENNER, STEVEN | 1999-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049008-A1 | Templated molecules and methods for using such molecules | INTS6, ABL1, INMT | RNASE1 278/4885LMNA 520/4885SMN1; SMN2 3576/4885 |
| US-20100016177-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | INTS6, ABL1, INMT | RNASE1 278/4885LMNA 520/4885SMN1; SMN2 3576/4885 |
| US-10669538-B2 | Templated molecules and methods for using such molecules | ABL1, DHFR, TYMS | RNASE1 88/4885LMNA 2667/4885SMN1; SMN2 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.